Melanotan.nl - Bruin worden in enkele weken

http://www.clinuvel.com/en/blog/?p=515

18/11 AGM!

Company Announcement
Wednesday 18th November 2009
Melbourne, Australia
Manager Companies
Company Announcements Office
Australian Securities Exchange Limited
Level 4, Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000
Dear Sir/Madam,
Results of Annual General Meeting
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.
Yours faithfully,
Darren Keamy
Company Secretary
Clinuvel Pharmaceuticals Limited
Proxy Summary
Annual General Meeting
Wednesday, 18 November 2009
1)
Adoption of the Remuneration Report
The instructions given to validly appointed proxies in respect of the resolution were as follows:
For
Against
Abstain
Proxy's discretion
16,932,926
3,623,111
724,014
1,068,618
carried
The motion was carried as an ordinary resolution on a show of hands
2)
Appointment of Grant Thornton Audit Pty Ltd
The instructions given to validly appointed proxies in respect of the resolution were as follows:
For
Against
Abstain
Proxy's discretion
20,116,502
313,486
850,063
1,068,618
carried
The motion was carried as an ordinary resolution on a show of hands
3)
Re-election of Mr Stanley McLiesh
The instructions given to validly appointed proxies in respect of the resolution were as follows:
For
Against
Abstain
Proxy's discretion
19,377,353
1,065,480
837,218
1,068,618
carried
The motion was carried as an ordinary resolution on a show of hands
4)
Re-election of Dr Helmer Agersborg
The instructions given to validly appointed proxies in respect of the resolution were as follows:
For
Against
Abstain
Proxy's discretion
16,926,404
3,304,574
877,968
1,239,723
carried
The motion was carried as an ordinary resolution on a show of hands
5)
Approve Conditional Performance Rights Plan
The instructions given to validly appointed proxies in respect of the resolution were as follows:
For
Against
Abstain
Proxy's discretion
15,759,294
4,845,202
303,580
523,342
carried
The motion was carried as an ordinary resolution on a show of hands
- End -
For more information contact:
Darren Keamy
Company Secretary
Clinuvel Pharmaceuticals Limited
T: +61 3 9660 4900
E: investorrelations@clinuvel.com
Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, afamelanotide for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:
•
actual results may and often will differ materially from these forward-looking statements;
•
no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for afamelanotide can or will be achieved;
•
no assurances can be given by Clinuvel that, even if its development programme for afamelanotide is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place
Level 11 / 330 Collins Street T +61 3 9660 4900 http://www.clinuvel.com
Melbourne, Victoria 3000 F +61 3 9660 4999
Australia

http://www.clinuvel.com/resources/cmsfi ... eeting.pdf

Trend Invest Report: Heiße Wette auf gute Phase-III-Daten

Bei der australischen Biotech-Schmiede Clinuvel (WKN A0J EGY) werden dem Trend Invest Report zufolge, noch vor Jahresfrist die "Karten auf den Tisch" gelegt. Das Unternehmen, welches sich auf die Erforschung von Wirkstoffen gegen schwere Hauterkrankungen spezialisiert hat, will für seinen am weitesten fortgeschrittenen Medikamentenkandidaten Afamelanotide noch in diesem Jahr Phase-III-Daten vorlegen, und zwar in der Indikation "Erythropoetische Protoporphyrie" (EPP). Hinter dem schwer auszusprechenden Namen verbirgt sich eine Stoffwechselstörung, die sich negativ auf die Blutbildung auswirkt. Das wiederum zeigt sich in einer schweren Lichtunverträglichkeit, die das Leben der Patienten stark einschränkt. Eine wirksame Therapie gibt es bislang nicht. Die Experten raten zum spekulativen Einstieg mit einer kleinen Position.

Interessant genoeg dus om aandelen hiervan aan te schaffen. Zal mijn man hier eens over inlichten...

http://www.clinuvel.com/resources/cmsfi ... letter.pdf

From Newsletter

Expected In Q1:
FDA response on EPP trial in US centres
Final results EPP PH III
Start EPP confirmatory Phase III trial
Final results confirmatory pharmacokinetic trial US

http://www.clinuvel.com/resources/cmsfi ... esults.pdf

CLINUVEL REPORTS POSITIVE RESULTS IN PHASE III PORPHYRIA
(EPP) CLINICAL TRIAL